Aspen Pharmacare Boss Stephen Saad is in the C SUITE
Saad says “Aspenovax is testament to the skills and capabilities within Aspen and their ability to deliver at the very highest level globally.
Aspen shares this proud moment with all of Africa. These results reflect both the strong operating performance within Aspen and a sound balance sheet. The progress being made to margins has been through the operationalisation of the significant historic investments.
Our highlight has been the delivery of 180m vaccines to Johnson & Johnson, almost all for Africa. The business has faced and continues to face unprecedented supply chain challenges as a result of COVID-19 related impacts, exacerbated by the conflict within Ukraine. We have built great momentum in the first half and providing the geopolitical challenges do not cause further deterioration, we are hopeful to repeat this performance into the second half. Our performance and capacities within our sterile manufacturing platform has created many more opportunities. We believe this demonstration of competence will be the enabler for the enhancement of future growth.”
Watch all episodes of the C-SUITE.
About Stephen Saad
Stephen is a founding shareholder of the Aspen Group and his responsibilities include strategic positioning and global transactions, geographic expansion and product diversification of Aspen in developed and emerging markets as a leading multinational pharmaceutical company.